Effect of Serotonin Uptake Inhibition on Breathing during Sleep and Daytime Symptoms in Obstructive Sleep Apnea

摘要: Pharmacologic enhancement of serotonergic transmission by serotonin uptake inhibition has been suggested as one approach to improve upper-airway patency and thus nocturnal breathing in patients with obstructive sleep apnea (OSA). To test this hypothesis, we performed a double-blind, randomized, placebo-controlled crossover study testing the effect paroxetine (20 mg od) on polysomnographic psychopathologic outcomes 20 male OSA (mean age 52.1 years, mean BMI 28.7 kg/m2, oxygen desaturation index previous screening 25.4/hour). The two treatment periods 6 weeks separating washout period 4 were completed 17 patients. Paroxetine reduced during NREM (-35%, p = 0.003), but not REM sleep. No significant hypopnea indices was found. With exception previously described REM-postponing (p 0.05), architecture significantly influenced paroxetine. Similarly, associated overall alleviation symptoms rated Comprehensive Psychopathological Rating Scale or OSA-related daytime complaints assessed visual analog scales. We conclude that enhanced improves OSA. This is poorly related effects symptoms.